Avitide Rolls Out Series A to Launch Biologics Purification Co.
This article was originally published in The Pink Sheet Daily
Avitide Inc. raised an undisclosed Series A financing from a strong and familiar syndicate to provide custom affinity purification solutions to biologics manufacturers.
You may also be interested in...
Polaris’ focus on people and platforms was never more evident than in 2013, when it leveraged its relationship with one entrepreneur in particular to great effect.
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.